Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
3(14%)
Results Posted
29%(2 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
4
19%
Ph not_applicable
3
14%
Ph phase_3
3
14%
Ph phase_1
6
29%
Ph phase_4
2
10%
Ph early_phase_1
1
5%

Phase Distribution

7

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution19 total trials
Early Phase 1First-in-human
1(5.3%)
Phase 1Safety & dosage
6(31.6%)
Phase 2Efficacy & side effects
4(21.1%)
Phase 3Large-scale testing
3(15.8%)
Phase 4Post-market surveillance
2(10.5%)
N/ANon-phased studies
3(15.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

3

trials recruiting

Total Trials

21

all time

Status Distribution
Active(3)
Completed(7)
Terminated(2)
Other(9)

Detailed Status

unknown8
Completed7
Recruiting3
Terminated1
Withdrawn1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
3
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (5.3%)
Phase 16 (31.6%)
Phase 24 (21.1%)
Phase 33 (15.8%)
Phase 42 (10.5%)
N/A3 (15.8%)

Trials by Status

terminated15%
completed733%
withdrawn15%
recruiting314%
suspended15%
unknown838%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT05842174Phase 1

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Recruiting
NCT05435014Phase 1

T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma

Suspended
NCT07395128Phase 1

Lateral Plantar Artery Embolization For Plantar Fasciitis

Recruiting
NCT04459468

Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

Completed
NCT04200417Phase 1

Chemoembolization for Lung Tumors

Completed
NCT06859164Phase 2

Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis

Recruiting
NCT02762266Phase 3

Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

Terminated
NCT04733092Phase 1

Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)

Completed
NCT05291338

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Completed
NCT01877187Phase 2

Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

Completed
NCT04048317Early Phase 1

Effectiveness of Drug Eluting TACE in Primary HCC

Unknown
NCT02585479Phase 2

Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma

Withdrawn
NCT03542331Phase 3

Endometrial Effects of Lipiodol

Unknown
NCT03617029Not Applicable

Localization for Deep Lung Nodules: Microcoil Versus Contrast Injection

Unknown
NCT02180568Not Applicable

Lipiodol Localization for Ground-glass-opacity Minimal Surgery

Completed
NCT01959061Phase 4

Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases

Unknown
NCT02755311Phase 3

Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma

Unknown
NCT01923064Not Applicable

Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices

Completed
NCT02638857Phase 1

Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

Unknown
NCT02631499Phase 4

Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
21